NASDAQ : FBRX
Forte Biosciences, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 76.99 USD (Aug 26, 2026, 4:00 PM EDT) · Market cap 1.94B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Selling, General & Admin | 15.05M | 12.41M | 15.41M | 10.62M | 8.30M | 7.63M |
| Research & Development | 79.74M | 58.25M | 21.19M | 21.86M | 5.59M | 13.85M |
| Operating Expenses | 94.80M | 70.66M | 36.60M | 32.49M | 13.90M | 21.49M |
| Operating Income | -94.80M | -70.66M | -36.60M | -32.49M | -13.90M | -21.49M |
| Interest & Investment Income | 2.71M | 2.71M | 1.31M | 1.12M | 162.00K | |
| Other Non Operating Income (Expenses) | 139.00K | -396.00K | -190.00K | -114.00K | -145.00K | -222.00K |
| EBT Excluding Unusual Items | -91.94M | -68.34M | -35.48M | -31.48M | -13.88M | -21.71M |
| Pretax Income | -86.33M | -68.34M | -35.48M | -31.48M | -13.88M | -21.71M |
| Income Tax Expense | 1.60M | 1.04M | ||||
| Net Income | -87.94M | -69.38M | -35.48M | -31.48M | -13.88M | -21.71M |
| Net Income to Common | -87.94M | -69.38M | -35.48M | -31.48M | -13.88M | -21.71M |
| Shares Outstanding (Basic) | 19.35M | 14.72M | 2.92M | 1.26M | 695.34K | 558.71K |
| Shares Outstanding (Diluted) | 19.35M | 14.72M | 2.92M | 1.26M | 695.34K | 558.71K |
| EPS (Basic) | -4.55 | -4.71 | -12.17 | -24.92 | -19.96 | -38.85 |
| EPS (Diluted) | -4.55 | -4.71 | -12.17 | -24.92 | -19.96 | -38.85 |
| Free Cash Flow | -72.03M | -51.00M | -30.78M | -28.79M | -8.19M | -16.68M |
| Free Cash Flow Per Share | -3.72 | -3.46 | -10.56 | -22.80 | -11.77 | -29.85 |
| EBITDA | -94.72M | -70.59M | -36.56M | -32.48M | -13.86M | -21.45M |
| D&A For EBITDA | 75.00K | 64.00K | 39.00K | 9.00K | 36.00K | 36.00K |
| EBIT | -94.80M | -70.66M | -36.60M | -32.49M | -13.90M | -21.49M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 49.63M | 76.96M | 22.24M | 37.12M | 41.10M | 42.04M |
| Short-Term Investments | 148.83M | 36.12M | ||||
| Cash & Short-Term Investments | 198.46M | 76.96M | 58.37M | 37.12M | 41.10M | 42.04M |
| Other Receivables | 813.00K | 817.00K | 128.00K | |||
| Receivables | 813.00K | 817.00K | 128.00K | |||
| Prepaid Expenses | 3.44M | 2.39M | 2.65M | 1.04M | 341.00K | 387.00K |
| Other Current Assets | 391.00K | 422.00K | 208.00K | 165.00K | 70.00K | 89.00K |
| Total Current Assets | 203.10M | 80.59M | 61.35M | 38.33M | 41.51M | 42.52M |
| Property, Plant & Equipment | 90.00K | 129.00K | 77.00K | 109.00K | ||
| Long-Term Deferred Charges | 106.00K | |||||
| Other Long-Term Assets | 2.55M | 2.06M | 138.00K | 544.00K | 486.00K | 680.00K |
| Total Assets | 205.74M | 82.78M | 61.56M | 38.98M | 42.00M | 43.31M |
| Accounts Payable | 14.01M | 9.99M | 4.88M | 1.42M | 1.15M | 946.00K |
| Accrued Expenses | 4.94M | 9.84M | 4.20M | 2.24M | 2.03M | 812.00K |
| Other Current Liabilities | 1.34M | 927.00K | ||||
| Total Current Liabilities | 20.29M | 20.75M | 9.08M | 3.67M | 3.18M | 1.76M |
| Other Long-Term Liabilities | 1.66M | 1.04M | ||||
| Total Liabilities | 21.95M | 21.79M | 9.08M | 3.67M | 3.18M | 1.76M |
| Common Stock | 21.00K | 13.00K | 6.00K | 1.00K | 21.00K | 15.00K |
| Additional Paid-In Capital | 452.67M | 284.35M | 206.46M | 153.83M | 125.84M | 114.70M |
| Retained Earnings | -268.84M | -223.37M | -154.00M | -118.52M | -87.04M | -73.17M |
| Comprehensive Income & Other | -54.00K | 3.00K | 11.00K | 4.00K | ||
| Total Common Equity | 183.79M | 60.99M | 52.48M | 35.31M | 38.82M | 41.55M |
| Shareholders' Equity | 183.79M | 60.99M | 52.48M | 35.31M | 38.82M | 41.55M |
| Total Liabilities & Equity | 205.74M | 82.78M | 61.56M | 38.98M | 42.00M | 43.31M |
| Net Cash (Debt) | 198.46M | 76.96M | 58.37M | 37.12M | 41.10M | 42.04M |
| Net Cash Per Share | 10.26 | 5.23 | 20.02 | 29.40 | 59.11 | 75.25 |
| Filing Date Shares Outstanding | 25.19M | 18.77M | 6.58M | 1.46M | 840.00K | 590.45K |
| Total Common Shares Outstanding | 24.44M | 17.83M | 6.39M | 1.45M | 840.00K | 590.18K |
| Working Capital | 182.81M | 59.84M | 52.27M | 34.66M | 38.33M | 40.76M |
| Book Value Per Share | 7.52 | 3.42 | 8.21 | 24.30 | 46.21 | 70.40 |
| Tangible Book Value | 183.79M | 60.99M | 52.48M | 35.31M | 38.82M | 41.55M |
| Tangible Book Value Per Share | 7.52 | 3.42 | 8.21 | 24.30 | 46.21 | 70.40 |
| Machinery | 241.00K | 241.00K | 125.00K | 118.00K |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Net Income | -87.94M | -69.38M | -35.48M | -31.48M | -13.88M | -21.71M |
| Depreciation & Amortization | 75.00K | 64.00K | 39.00K | 9.00K | 36.00K | |
| Asset Writedown & Restructuring Costs | 61.00K | |||||
| Loss (Gain) From Sale of Investments | -1.04M | -237.00K | -158.00K | -131.00K | ||
| Stock-Based Compensation | 9.99M | 6.26M | 3.10M | 3.28M | 4.01M | 4.21M |
| Change in Accounts Payable | 8.54M | 5.54M | 3.02M | 271.00K | 207.00K | -294.00K |
| Change in Income Taxes | 1.04M | 1.04M | ||||
| Change in Other Net Operating Assets | -2.63M | 5.83M | -1.26M | -663.00K | 1.47M | 1.01M |
| Operating Cash Flow | -71.98M | -50.88M | -30.75M | -28.71M | -8.19M | -16.68M |
| Capital Expenditures | -55.00K | -116.00K | -37.00K | -88.00K | ||
| Investment in Securities | -147.84M | 36.35M | -35.96M | 135.00K | ||
| Investing Cash Flow | -147.90M | 36.23M | -35.99M | 47.00K | ||
| Issuance of Common Stock | 174.45M | 76.83M | 53.01M | 25.02M | 7.24M | 62.00K |
| Repurchase of Common Stock | -49.00K | -29.00K | -35.00K | -60.00K | ||
| Other Financing Activities | -11.04M | -7.44M | -1.12M | -272.00K | -106.00K | |
| Financing Cash Flow | 163.36M | 69.36M | 51.86M | 24.68M | 7.24M | -44.00K |
| Net Cash Flow | -56.52M | 54.71M | -14.88M | -3.98M | -944.00K | -16.72M |
| Free Cash Flow | -72.03M | -51.00M | -30.78M | -28.79M | -8.19M | -16.68M |
| Free Cash Flow Per Share | -3.72 | -3.46 | -10.56 | -22.80 | -11.77 | -29.85 |
| Levered Free Cash Flow | -41.29M | -26.94M | -16.14M | -17.40M | -3.18M | -9.02M |
| Unlevered Free Cash Flow | -41.29M | -26.94M | -16.14M | -17.40M | -3.18M | -9.02M |
| Change in Working Capital | 6.95M | 12.41M | 1.76M | -392.00K | 1.68M | 720.00K |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 1.94B | 486.26M | 145.19M | 29.86M | 21.00M | 31.57M |
| Enterprise Value | 1.74B | 392.85M | 128.83M | -16.33M | -23.05M | -14.09M |
| Last Close Price | 76.99 | 27.27 | 22.71 | 20.54 | 25.00 | 53.50 |
| PB Ratio | 10.24 | 7.97 | 2.77 | 0.84 | 0.54 | 0.76 |
| P/TBV Ratio | 10.55 | 7.97 | 2.77 | 0.84 | 0.54 | 0.76 |
| Net Debt / Equity Ratio | -1.08 | -1.26 | -1.11 | -1.05 | -1.06 | -1.01 |
| Net Debt / EBITDA Ratio | 2.10 | 1.09 | 1.60 | 1.14 | 2.96 | 1.96 |
| Net Debt / FCF Ratio | 2.75 | 1.51 | 1.90 | 1.29 | 5.02 | 2.52 |
| Quick Ratio | 9.82 | 3.75 | 6.44 | 10.13 | 12.93 | 23.92 |
| Current Ratio | 10.01 | 3.88 | 6.75 | 10.46 | 13.06 | 24.19 |
| Return on Equity (ROE) | -62.28% | -122.28% | -80.82% | -84.92% | -34.54% | -43.19% |
| Return on Assets (ROA) | -37.79% | -61.19% | -45.51% | -50.15% | -20.36% | -25.69% |
| Return on Capital Employed (ROCE) | -51.10% | -113.90% | -69.70% | -92.00% | -35.80% | -51.70% |
| Earnings Yield | -4.54% | -14.27% | -24.44% | -105.42% | -66.09% | -68.75% |
| FCF Yield | -3.71% | -10.49% | -21.20% | -96.44% | -38.98% | -52.82% |
| Buyback Yield / Dilution | -148.66% | -404.74% | -130.90% | -81.61% | -24.45% | -89.81% |